ClinicalTrials.gg
RecruitingNCT07016815TOM-HFUpdated Nov 18, 2026

Accelerated Optimization of Foundational Medical Therapy in Acute Decompensation of Heart Failure by Telemonitoring: A Pragmatic Multi-center Randomized and Cost-Effectiveness Study

An interventional study of Wearable wrist heart rate and activity monitor and Bluetooth enabled body weight scale with bioimpedance analysis in Acute Heart Failure With Reduced Left Ventricular Ejection Fraction, sponsored by Chinese University of Hong Kong. Recruiting at 8 sites in Hong Kong. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 18, 2026Start date movedEnrollment updated+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Heart Failure by Chinese University of Hong Kong — 7 open to participants now, 7 under way, 1 of them phase 3. Heart Failure · Chinese University of Hong Kong.

Started
2027
the only one that year
No phase
7 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Heart Failure by Chinese University of Hong Kong, this one is the only one that started in 2027, is one of 7 with no phase, and was the 13th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 15 studies in Heart Failure by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Problem: Aggressive titration of guideline-directed medical therapy is the cornerstone of heart failure management to reduce heart failure related hospitalization and mortality. A major hurdle to uptitration of medical therapy is the safety concerns of these medications namely hypotension and bradycardia. Early and frequent clinic visits will be required to ensure the safe uptitration of these treatments, but this is difficult to implement in daily practice due to resources constrain. Advancement in wearable and wireless technologies enables remote and continuous monitoring of patients in ambulatory setting and potentially achieving safe and effective uptitration of medical therapy while minimizing the demand on the current healthcare system. However, access to these wearable and wireless technologies is not universal and patients in low socio-economic tiers might be deprived of the opportunity to realize the benefits from these technologies.

Solution: This project therefore aims to develop a mobile platform and to provide wearable devices to patients with acute heart failure to improve and optimize the use of guideline-directed medical therapy in these patients.

Impacts: The finding from this project will inform future heart failure management and help to implement and integrate telemedicine in the vulnerable stage of heart failure care. It will help to maximize healthcare resources utilization and help to bridge the gap between those who have limited access to healthcare services. The model of heart failure care generated from this project can be propagate and replicated in general patients care.

Read the detailed description

Optimal and aggressive titration of guideline-directed medical therapy (GDMT) is the cornerstone of heart failure (HF) management to reduce HF related hospitalization and improve patient survival1. However, the percentage of patient achieving targeted dose of GDMT in real-world setting is consistently low across different regions2,3,4. Failure to achieve targeted dose of GDMT has been a main factor contributing to the high mortality of HF patients1. A major hurdle to up-titration of GDMT is the therapeutic inertia5 on the part of the treatment providers partly due to safety concerns for these medication namely symptomatic hypotension and bradycardia. The safety concern is especially great in patients with acute decompensated HF in whom fluctuation in hemodynamic can be substantial. Therefore, the major challenge in HF care is the attainment of optimal dose of GDMT without increasing serious adverse effect to the patients. Two approaches to patient care have been proposed to overcome this challenge. Patients can be either kept inpatient for medication up-titration5,6 or followed up by intensive outpatient clinic visits. Recently the STRONG-HF study has demonstrated the feasibility of rapid up-titration of GDMT through frequent outpatient clinic visits7. However, neither of these approaches is feasible in the local setting given the severe hospital bed and healthcare manpower shortage in Hong Kong public healthcare system. Remote monitoring (RM) has been used in chronic HF patients with aims to reduce clinic visits and improve HF care but has not been demonstrated uniformly beneficial in various studies9,10,11. Large part of the lack of benefit of RM in these clinical trials might be attributed to poor adherence to devices usage in the long term (50% of adherence) and a lack of a clearly defined actionable plan to the data received. Since then, significant advancement has been made in wireless and wearable technologies. Continuous monitoring and automatic transmission of patient hemodynamic data may mitigate the non-adherence issues of RM. As only a finite period of medication titration is generally required to achieve maximum tolerated dose of GDMT in HF patients, RM potentially may play a role in facilitating rapid medication up-titration and maximizing healthcare resources utilization during the initial phase of acute HF care.

Aims and Hypotheses to be Tested:

Study question: Can ambulatory telemonitoring improve and optimize guideline-directed medical therapy (GDMT) in patients with acute heart failure?

Study hypothesis: Telemonitoring can yield more efficient up-titration of GDMT to targeted dose in patients with acute heart failure than routine physical clinic visit.

Study aims:

  1. to compare the percentage of targeted GDMT dose attainment in patients subjected to intensive medication up-titration guided by integrated telemonitoring against patients in routine medical care.
  2. To evaluate the feasibility and safety of aggressive GDMT titration as guided by telemonitoring.
  3. To evaluate the adherence and acceptance of modern commercially available wireless telemonitoring devices in HF patients.
  4. To evaluate the impact of wearable telemonitoring on the quality of life of HF patients
  5. To assess the role of different parameters and components from telemonitoring in predicting HF decompensation and adverse events from medications.

Plan of Investigation:

This is a prospective, open-labelled, single-centre, randomized controlled trial comparing telemonitoring (intervention) in patients with acute heart failure (HF) with routine clinical care (control). Eligible patient will be recruited primarily from Prince of Wales Hospital by both the Cardiologists and Internal Medicine physicians.

(i) Subjects (with justification on the sample size)

The target patients are those aged >18, who are hospitalized for first episode of acute decompensate heart failure, which is defined by all of the following criteria:

  1. Clinical symptoms of Dyspnoea (exertional or at rest) and 1 of the following signs:

    • Congestion on chest X-ray
    • Rales on chest auscultation
    • Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale)
    • Elevated jugular venous pressure.
  2. NT-proBNP which is measured within the same hospitalization with level >300ng/L or 600ng/L if ongoing atrial fibrillation/atrial flutter.
  3. Left ventricular ejection fraction less than 40% by any form of imaging.

Exclusion criteria:

  1. Documented history of HF with previous HF admission.
  2. Current hospitalization for acute HF primarily triggered by pulmonary embolism, cerebrovascular accident, or acute MI.
  3. Cardiac interventions (listed below) in past 30 days prior or planned during the study period.

    1. Major cardiac surgery, or Tran Aortic Valve Implantation, or Percutaneous Coronary Intervention, or MitraClip
    2. Current or expected heart transplant, LVAD, IABP, or patients with planned inotropic support in an outpatient setting.
  4. Haemodynamically severe uncorrected primary cardiac valvular disease.
  5. eGFR \<30 mL/min/1.73m2 as measured during index hospitalization (latest measurement before randomization) or patients requiring dialysis.
  6. Documented allergy or intolerance to beta-blocker, renin-angiotensin-aldosterone system inhibitor, mineralocortical receptor antagonist, or angiotensin receptor/neprilysin inhibitor.
  7. Pregnant or nursing women.
  8. Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months.
  9. Non-ambulatory patients.
  10. Patients who are unable to operate simple electronic devices; or unable to assess a mobile network service in the place of residence.
  11. Patients who are unable to given written informed consent.

Sample size calculation:

From previous HF registry conducted at local sites and from previous published data from the same locality, the percentage of GDMT use in HF patients under routine care is around 20%. Assuming the percentage of targeted dose GDMT attainment to be 50% in the intervention arm7, an estimate of 56 patients with 28 in each arm is needed to show a significant difference between two groups, with a 5% significance level and 80% power. Assuming the drop-out rate to be 30%, a total of 80 patients with 40 patients in each arm will be required.

(ii) Methods The study will be conducted according to the Declaration of Helsinki and comply with ICH-GCP. Institutional Ethics approval will be obtained, and the trial will be registered at Clinicaltrials.gov before the start of this study. Subjects will be recruited from Prince of Wales Hospital medical inpatient units. Written informed consent will be taken from each recruited subject. Patients meeting eligibility criteria will be randomized via a freely accessible interactive web response system (www.randomization.com) to one of the two study arms in a 1:1 ratio, according to a central randomization scheme.

After recruitment, baseline information including patient's demographics, past medical history, discharge medication history, baseline laboratory, and baseline echocardiography will be collected.

As a background CHF treatment, one of the Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor either Empagliflozin 10mg daily or Dapagliflozin 10mg daily will be started before discharge as this class of drug does not require any dose up-titration12,13. Other classes of HF drug such as beta-blocker (BB), mineralocortical receptor antagonist (MRA), or angiotensin receptor/neprilysin inhibitor (ARNI) will be initiated and titrated by physicians during the index admission according to their clinical judgement before discharge.

(iii) Study design This is a prospective, open-labelled, single-centre, randomized controlled trial consisting of an intervention group and a control group. A physical clinic visit with cardiologist consultation will be scheduled for both groups every 30 days with blood testing for NT-proBNP and renal function until 90 days. At 90 days, a follow-up echocardiogram will be performed for both groups of patients with the primary aim of left ventricular function evaluation. The follow-up period for both groups is 90 days. The proposed study duration is 24 months.

Intervention group Patients randomized to the intervention group will be taught how to operate individual devices of telemonitoring before discharge by the research team. 30 days of all three classes medication up to the targeted dose (as listed below) will be given to the patient with clear labelling and instructions on their administration. Pills of minimal dosage will be provided for easier patient communication and dosage titration. Medication up-titration will be performed over the phone by a senior research nurse according to algorithms as listed below. Patients will also be asked during each phone call regarding the occurrence of any adverse event.

The integrated telemonitoring consists of 1. a wearable wrist heart rate and activity monitor, 2.a blue-tooth enabled body weight scale with bioimpedance analysis, and 3. a blue-tooth enabled electronic blood pressure device.

  1. Wearable wrist heart rate and activity monitor: A commercially available smart watch capable of continuous monitoring of heart rate and activities including daily steps count and daily activity level, detection of arrythmia using a proprietary FDA approved algorithm14, and measuring peripheral capillary oxygen saturation will be provided to the patient. Patients will be encouraged to wear the watch as often as possible during daytime and during sleep. Data gathered will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patient.
  2. Bluetooth enabled body weight scale with bioimpedance analysis: An electronic scale which measures bioimpedance using bioelectrical analysis from foot-to-foot impedance and body fluid percentage (BF%) using a proprietary equation15,16 will be provided to the patients. Patient will be encouraged to measure their bodyweight (BW) and bioimpedance twice per day, one in the morning, and one before bath, with minimal clothing. Both data will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patients.
  3. Bluetooth enabled electronic blood pressure device: An electronic cuffed arm blood pressure monitor will be provided to the patient with instruction on how to perform proper blood pressure measurement at home16. Patients are encouraged to take at least 2 blood pressure reading daily, one in the morning and one in the evening. Blood pressure reading will be transmitted wirelessly to an online platform provided by the manufacturer accessible only by the research team and the patients.

Uploaded hemodynamic and biological data will be reviewed by the research team on a daily basis.

Medication up-titration scheme

Up-titration of medication will be performed over the phone every 3 days by a senior research nurse until the maximum tolerated dose is reached. In patient in whom any 1 of the 3 classes of GDMT has not been started upon discharge, the starting dose of the missing class of GDMT will be started first. In patient in whom none of the GDMT has been started upon discharge, the medication will be started with the starting dose as listed in the sequence of MRA -> BB -> ARNI. In patient in whom all 3 classes of GDMT has been started upon discharge, the sequence of medication titration is as followed: MRA -> BB -> ARNI, with aim of up-titration to the maximum dose of 1 class followed by the next class. This approach has been evaluated in a simulated model to be the most effective in reducing HF related hospitalization18. The maximum dose is defined by the suggested target dose1 (as listed below) or the maximum tolerated dose without side effect, whichever is higher. The next escalating dose of any class will not be initiated if systolic blood pressure is less than 90mmHg. Additionally, the next escalating dose of ARNI or MRA will not be initiated if weekly blood test showed serum potassium greater than 5.5mmol/L, or if estimated GFR \<30ml/min/1.73m2, or if serum creatinine level rise above 30% over baseline. Also, the next escalating dose of BB will not be initiated if systolic blood pressure is less than 90mmHg or if the lowest heart rate on the 24 hours monitor is less than 40 beat/min or the average heart rate is less than 55 beat/min. If any severe adverse event is encountered after up-titration of medication dose, patient will be instructed to fall back on the previous dose. If the adverse event resolved on the next up-titration schedule, patient will be instructed to up-titrate the previous drug dose again. If similar adverse event arises again, then the previous dose will be considered the maximum tolerated dose. The suggested medications starting and target dose for each individual class of GDMT are as followed1:

  1. Mineralocortical receptor antagonist - Eplerenone starting dose 25mg daily with 25mg daily increment until target dose of 50mg daily; Spironolactone starting dose 25mg daily with 25mg daily increment until target dose of 50mg daily.
  2. Beta-blocker: Bisoprolol starting dose 1.25mg daily with 1.25mg daily increment until target dose of 10mg daily; Carvedilol starting dose 3.125mg twice daily with 3.125mg twice daily increment until target dose of 25mg twice daily; Metoprolol succinate starting dose 25mg daily with 25mg daily increment until target dose of 200mg daily.
  3. Angiotensin receptor/neprilysin inhibitor - Sacubitril/valsartan starting dose 24/26 mg twice daily with 24/26 mg twice daily increment until target dose of 97/103 mg twice daily.

Blood checking for renal function, electrolytes and Point-of-care NT-proBNP will be performed weekly during the medication up-titration period for safety reason until the maximum dose is reached.

Control Group Patient will be seen at clinic for physician consultation every 30 days after discharge as per current practice until the end of follow-up which is at 90 days. Guidance on medication up-titration similar to intervention group will be provided to the physician. Medication titration will be performed during clinic consultation at the physician's discretion.

Outcomes Primary outcomes: Percentage of patients receiving target dose of individual class of GDMT which is defined as above1 at 90 days.

Secondary outcomes:

  • Wearable device and monitoring adherence in the intervention group.
  • Difference in New York Heart Association (NYHA) functional class, 6 minutes' walk test, heart failure related quality of life measure (by EQ-5D questionnaire) at 90 days.
  • Difference in NT-proBNP level at 90 days.
  • Unscheduled medical visit.
  • HF related Hospitalization.
  • HF related mortality and all-cause mortality. Safety outcomes: Occurrence of any Serious Adverse Event which is defined as
  • fatal or life-threatening events,
  • resulting in persistent or significant disability/incapacity
  • requiring inpatient hospitalization or prolongation of existing hospitalization,
  • being medically significant, i.e. defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above.

Data processing and analysis All data were reported as mean ± SD unless otherwise specified. Following the intent-to-treat principle, patients will be analyzed according to the arm to which they were assigned. The primary outcome, difference in the percentage of patients receiving targe dose of individual class of GDMT at 90 days will be compared between the two groups using unpaired Student t-test. Other parameters and outcomes will be compared between baseline and at 90 days, as well as between the 2 groups. Student's t test and Mann-Whitney U test will be used for continuous variables while Chi-squared test and Fisher's exact test will be used to compare categorical variables, where appropriate. Two groups will be compared with respect to the change in NT-proBNP level at baseline and at 90-days using ANCOVA with the baseline value and randomization stratification factors as covariates. Central laboratory measures of NT-proBNP will be log-transformed for this analysis. All tests were two-sided, with significance set at 5%.

Additionally, a cost-effective analysis will be performed on the total cost incurred in both groups and incremental cost-effectiveness ratio expressed as incremental cost per hospitalization avoided at day 0, day 15, day 30, and day 90, based on data from the stimulated model18 will be calculated. All cost data will be expressed in Hong Kong dollar and valued on the starting date of the study from a healthcare system perspective (i.e., all the medical costs will be valued on the basis of non-subsidized cost). The average cost difference between the intervention and control groups will be used to derive the incremental total cost (or total cost saved). All statistical analyses will be performed using STATA version 15 software (College Station, TX, USA).

03

Conditions studied

  • Acute Heart Failure With Reduced Left Ventricular Ejection Fraction

Browse trials for

Keywords

  • telemonitoring
  • wearable
  • HFrEF
  • titration
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical symptoms of Dyspnoea (exertional or at rest) and 1 of the following signs:

    • Congestion on chest X-ray
    • Rales on chest auscultation
    • oedema (e.g. ≥1+ on a 0 to 3+ scale)
    • Elevated jugular venous pressure.
  2. NT-proBNP which is measured within the same hospitalization with level >300ng/L or 600ng/L if ongoing atrial fibrillation/atrial flutter.
  3. less than 40% by echocardiography.

Exclusion criteria

Exclusion Criteria:

  1. Documented history of HF with previous HF admission.
  2. Current hospitalization for acute HF primarily triggered by pulmonary embolism, cerebrovascular accident, or acute MI.
  3. Cardiac interventions (listed below) in past 30 days prior or planned during the study period.

    1. Major cardiac surgery, or Tran Aortic Valve Implantation, or Percutaneous Coronary Intervention, or MitraClip
    2. Current or expected heart transplant, LVAD, IABP, or patients with planned inotropic support in an outpatient setting.
  4. Haemodynamically severe uncorrected primary cardiac valvular disease.
  5. \<30 mL/min/1.73m2 as measured during index hospitalization (latest measurement before randomization) or patients requiring dialysis.
  6. Documented allergy or intolerance to beta-blocker, renin-angiotensin-aldosterone system inhibitor, mineralocortical receptor antagonist, or angiotensin receptor/neprilysin inhibitor.
  7. Pregnant or nursing women.
  8. Psychiatric or severe neurological disorder, cirrhosis, or active leading to a \< 6 months.
  9. Non-ambulatory patients.
  10. Patients who are unable to operate simple electronic devices; or unable to assess a mobile network service in the place of residence.
  11. Patients who are unable to given written .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Participants assigned to the intervention arm will receive brief training on the use of the telemonitoring device and the TOM-HF application, confined within the first 4 weeks. Heart failure medication will be initiated at the lowest available dose before discharge unless considered clinically inappropriate by the site PI. The core intervention is an accelerated, protocolized remote medication titration process integrating daily biometric and clinical information. Medication titration will be considered every Medication titration will be considered every 1-2 days during the first 4 weeks, according to a prespecified guideline-based algorithm and the patient's physiological data. Medication instructions will be delivered through a closed-loop process: incorporating in-app medication display, push notifications, and patient acknowledgement. Renal function and electrolytes will be tested at affiliated community blood taking centers, with the result reviewed remotely by the study team.

    Device: Wearable wrist heart rate and activity monitor · Device: Bluetooth enabled body weight scale with bioimpedance analysis · Device: Bluetooth enabled electronic blood pressure device · Device: mobile application

  • No intervention
    Control Group

    Participants randomized to the control arm will receive the same telemonitoring device and mobile application but will not undergo protocolized remote medication titration. Medication titration will instead be performed during scheduled specialist HF clinic at 4-6 weeks intervals at the discretion of the treating physicians, following the same guideline-based treatment framework as in the intervention arm.

Interventions

  • DeviceWearable wrist heart rate and activity monitor

    A commercially available smart watch capable of continuous monitoring of heart rate and activities including daily steps count and daily activity level, detection of arrythmia using a proprietary FDA approved algorithm14, and measuring peripheral capillary oxygen saturation will be provided to the patient. Patients will be encouraged to wear the watch as often as possible during daytime and during sleep. Data gathered will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patient.

    Also known as: smart watch

  • DeviceBluetooth enabled body weight scale with bioimpedance analysis

    An electronic scale which measures bioimpedance using bioelectrical analysis from foot-to-foot impedance and body fluid percentage (BF%) using a proprietary equation15,16 will be provided to the patients. Patient will be encouraged to measure their bodyweight (BW) and bioimpedance twice per day, one in the morning, and one before bath, with minimal clothing. Both data will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patients.

  • DeviceBluetooth enabled electronic blood pressure device

    An electronic cuffed arm blood pressure monitor will be provided to the patient with instruction on how to perform proper blood pressure measurement at home16. Patients are encouraged to take at least 2 blood pressure reading daily, one in the morning and one in the evening. Blood pressure reading will be transmitted wirelessly to an online platform provided by the manufacturer accessible only by the research team and the patients.

  • Devicemobile application

    a mobile Application through which data from remote monitoring and wearables will be incorporated, and instruction for medication titration and education on heart failure management will be provided to the patients.

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving left ventricular reverse remodeling (LVRR) at 90 days.

    The primary endpoint will be the proportion of patients achieving LVRR at 90 days. LVRR is defined as either an absolute increase in LVEF of ≥10 percentage points or a relative reduction in LVESV of ≥15% from baseline44. Echocardiography will be performed locally by sonographers independent of study and blinded to treatment allocation and imaging time point. Anonymized images will be uploaded to a central server for analysis by an independent core laboratory. Both LVEF and LVESV will be measured using the Biplane Simpson's method according to the guidelines. LVRR was selected as the primary endpoint as it provides an objective measure of treatment-associated cardiac recovery and has important prognostic significance in patients with HFrEF.

    Time frame: 90 days

Secondary outcomes

  1. modified Heart Failure Collaboratory (mHFC) score at 90 days

    mHFC is a validated, continuous measure of GDMT intensity that captures multi-drug, multi-dose optimization and has been associated with clinical outcomes in HFrEF, at 12th week. The mHFC score quantifies treatment intensity by assigning points to each foundational GDMT class according to target-dose proportion (0, \<50%, ≥50%). Sacubitril/valsartan components were scored separately, yielding a raw score of 0-8, transformed to 0-100. Higher scores indicate more complete implementation and dose optimization of guideline-directed medical therapy, reflecting a more favorable treatment profile.

    Time frame: 90 days

  2. Difference in New York Heart Association (NYHA) functional class

    The New York Heart Association (NYHA) functional class helps to classify congestive heart failure patients based on their symptoms. Class I: No symptoms of heart failure. Class II: Symptoms of heart failure with moderate exertion, such as ambulating two blocks or two flights of stairs. Class III: Symptoms of heart failure with minimal exertion, such as ambulating one block or one flight of stairs, but no symptoms at rest. Class IV: Symptoms of heart failure at rest.

    Time frame: baseline, 30, 60 and 90 days

  3. Composite adherence rate

    Composite adherence, defined as the mean of adherence across two components: percentage of completion of the required home-monitoring data uploads and percentage of acknowledgement of medication instructions.

    Time frame: 30 days

  4. Difference in 6 minutes' walk test

    The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Time frame: baseline, 30, 60 and 90 days

  5. Difference in heart failure related quality of life measure (by EQ-5D questionnaire)

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: baseline, 30, 60 and 90 days

  6. Difference in NT-proBNP level at 90 days

    N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a circulating biomarker released in response to increased myocardial wall stress and is widely used for the assessment of heart failure severity and prognosis. NT-proBNP levels will be measured at baseline and at 30, 60, and 90 days.

    Time frame: baseline, 30, 60, and 90 days

  7. Safety Events

    Occurrence of any of the followings: severe hypotension (SBP \<90 mm Hg), bradycardia (heart rate \<50 bpm), severe hyperkalemia (potassium \>5.5 mmol/L), worsening of renal function (defined as creatinine increase \>30% from baseline), and any adverse drugs reactions.

    Time frame: baseline till 90 days

  8. Heart failure (HF) related Hospitalization

    HF related Hospitalization

    Time frame: baseline, 90 days

  9. Heart failure (HF) related mortality and all-cause mortality

    HF related mortality and all-cause mortality

    Time frame: baseline, 90 days

  10. System Usability Scale (SUS)

    The System Usability Scale (SUS) is a validated 10-item questionnaire used to assess users' perceived usability of a system. Each item is rated on a 5-point Likert scale, and responses are converted to an overall score ranging from 0 to 100, with higher scores indicating greater perceived usability.

    Time frame: 30 days

Other outcomes

  1. Occurrence of any Serious Adverse Event

    Occurrence of any Serious Adverse Event which is defined as * fatal or life-threatening events, * resulting in persistent or significant disability/incapacity * requiring inpatient hospitalization or prolongation of existing hospitalization, * being medically significant, i.e. defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: baseline, 90 days

07

Study locations

2 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 23 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Jun 2025 → Jan 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 12, 2025
StartEst.
Jan 1, 2027was Jun 2025
Primary completionEst.
Dec 1, 2028
CompletionEst.
Feb 28, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 1 site removed
Show 7 added (7 Hong Kong)
  • Prince of Wales Hospital · Hong Kong, Hong Kong
  • Prince of Wales Hospital · Hong Kong, Hong Kong
  • Princess Margaret Hospital · Hong Kong, Hong Kong
  • Queen Elizabeth Hospital · Hong Kong, Hong Kong
  • Queen Mary Hospital · Hong Kong, Hong Kong
  • Tuen Mun Hospital · Hong Kong, Hong Kong
  • United Christian Hospital · Hong Kong, Hong Kong
Show 1 removed
  • Prince of Wales Hospital · Hong Kong, Hong Kong
Nov 18, 2026
Start date
Jun 1, 2025→Jan 1, 2027
Nov 18, 2026
Enrollment
80→126
Nov 18, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedLeft ventricular ejection fraction less than 40% by any form of imagingechocardiography.
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore The proportion of patients receiving target dose of each individual class of GDMTNow The proportion of patients achieving left ventricular reverse remodeling (LVRR) at 90 days.Time frame: 90 days
Nov 18, 2026
Secondary outcomes
2 edited, 3 added, 1 removed
What changed in the outcomes
  • EditedAdherenceComposite adherence rateTime frame: 90 days → 30 days
  • EditedDifference in NT-proBNP level at 90 daysTime frame: baseline, 30, 60, and 90 days
  • Addedmodified Heart Failure Collaboratory (mHFC) score at 90 daysTime frame: 90 days
  • AddedSafety EventsTime frame: baseline till 90 days
  • AddedSystem Usability Scale (SUS)Time frame: 30 days
  • RemovedUnscheduled medical visit.Time frame: baseline, 90 days
Nov 18, 2026
Title
Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study→Accelerated Optimization of Foundational Medical Therapy in Acute Decompensation of Heart Failure by Telemonitoring: A Pragmatic Multi-center Randomized and Cost-Effectiveness Study
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    7 sites added, 1 site removed
    Show 7 added (7 Hong Kong)
    • Prince of Wales Hospital · Hong Kong, Hong Kong
    • Prince of Wales Hospital · Hong Kong, Hong Kong
    • Princess Margaret Hospital · Hong Kong, Hong Kong
    • Queen Elizabeth Hospital · Hong Kong, Hong Kong
    • Queen Mary Hospital · Hong Kong, Hong Kong
    • Tuen Mun Hospital · Hong Kong, Hong Kong
    • United Christian Hospital · Hong Kong, Hong Kong
    Show 1 removed
    • Prince of Wales Hospital · Hong Kong, Hong Kong
    Start date Jun 1, 2025→Jan 1, 2027
    Enrollment 80→126
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedLeft ventricular ejection fraction less than 40% by any form of imagingechocardiography.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore The proportion of patients receiving target dose of each individual class of GDMTNow The proportion of patients achieving left ventricular reverse remodeling (LVRR) at 90 days.Time frame: 90 days
    Secondary outcomes 2 edited, 3 added, 1 removed
    What changed in the outcomes
    • EditedAdherenceComposite adherence rateTime frame: 90 days → 30 days
    • EditedDifference in NT-proBNP level at 90 daysTime frame: baseline, 30, 60, and 90 days
    • Addedmodified Heart Failure Collaboratory (mHFC) score at 90 daysTime frame: 90 days
    • AddedSafety EventsTime frame: baseline till 90 days
    • AddedSystem Usability Scale (SUS)Time frame: 30 days
    • RemovedUnscheduled medical visit.Time frame: baseline, 90 days
    Title Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study→Accelerated Optimization of Foundational Medical Therapy in Acute Decompensation of Heart Failure by Telemonitoring: A Pragmatic Multi-center Randomized and Cost-Effectiveness Study
    + 3 other changes: verification date, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07016815
Responsible party
GuangMing Tan (Assistant professor, Chinese University of Hong Kong) — Principal investigator
First posted
Jun 12, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Daniel Xu
Contact
gtan@cuhk.edu.hk
852+35051518
Kimmy Ho
Contact
kimmyho@cuhk.edu.hk
852+35051518

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion